hanmi pharmaceutical co ltd

Sanofi & Hanmi To Partner On New Diabetes Drugs

The Sanofi-Hanmi deal centers around longer-lasting biologics, which could reduce the frequency of treatment and dosage required for diabetic patients.

Lilly & Hanmi Ink US$690 Million Deal

Eli Lilly has acquired Hanmi's BTK inhibitor HM71224, a small molecule soon to enter Phase II trials for autoimmune diseases.

Hanmi Licenses Poziotinib To Luye Pharma

Luye acquires the rights to Poziotinib, Hanmi's pan-HER inhibitor for the treatment of cancer.

Kinex Pharma To Lead Orascovery Program In China

Kinex Pharma will lead Hanmi Pharma's Orascovery program development in China.